ES2063914T3 - Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso. - Google Patents

Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso.

Info

Publication number
ES2063914T3
ES2063914T3 ES90301212T ES90301212T ES2063914T3 ES 2063914 T3 ES2063914 T3 ES 2063914T3 ES 90301212 T ES90301212 T ES 90301212T ES 90301212 T ES90301212 T ES 90301212T ES 2063914 T3 ES2063914 T3 ES 2063914T3
Authority
ES
Spain
Prior art keywords
cell lines
packaging
defectuous
hiv provirus
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301212T
Other languages
English (en)
Inventor
Joseph Sodroski
William A Haseltine
Heinrich Gottlinger
Andrew Lever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2063914T3 publication Critical patent/ES2063914T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ES DESCUBIERTO UN VECTOR HIV DEFECTUOSO DE EMPAQUETADO. ESTE VECTOR PUEDE SER USADO PARA ESTABLECER LAS LINEAS CELULARES DEFECTUOSAS DE EMPAQUETADO. ESTAS LINEAS CELULARES PUEDEN SER USADAS EN DESARROLLAR UNA VACUNA, ANTICUERPOS HIV Y COMO PARTE DE UN SISTEMA PARA TRANSFERENCIA DE GEN.
ES90301212T 1989-02-06 1990-02-06 Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso. Expired - Lifetime ES2063914T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30766489A 1989-02-06 1989-02-06

Publications (1)

Publication Number Publication Date
ES2063914T3 true ES2063914T3 (es) 1995-01-16

Family

ID=23190695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301212T Expired - Lifetime ES2063914T3 (es) 1989-02-06 1990-02-06 Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso.

Country Status (7)

Country Link
EP (1) EP0386882B1 (es)
JP (1) JP3140757B2 (es)
AT (1) ATE111529T1 (es)
CA (1) CA2009403C (es)
DE (1) DE69012379T2 (es)
DK (1) DK0386882T3 (es)
ES (1) ES2063914T3 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
EP0487587A1 (en) * 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
JPH05501201A (ja) * 1989-10-16 1993-03-11 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 非感染性ｈｉｖ―１粒子およびそれらの使用
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
KR100372934B1 (ko) 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
CN1062601C (zh) * 1992-03-24 2001-02-28 剑桥药物研究有限公司 病毒疫苗
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
DK1473369T3 (da) * 1993-01-26 2009-03-09 Univ Pennsylvania Præparater og fremgangsmåde til administration af genetisk materiale
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
AU7263994A (en) * 1993-08-06 1995-02-28 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
EP1961813B1 (en) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
ES2380803T3 (es) 2005-11-14 2012-05-18 Centre National De La Recherche Scientifique (Cnrs) Dominio no histona MACROH2A como inhibidor de la actividad PARP-1 y uso del mismo
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
DK2694101T3 (en) 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CH684094A5 (de) * 1988-03-21 1994-07-15 Viagene Inc Rekombinante Retroviren.

Also Published As

Publication number Publication date
DE69012379D1 (de) 1994-10-20
JP3140757B2 (ja) 2001-03-05
EP0386882A1 (en) 1990-09-12
JPH0361492A (ja) 1991-03-18
CA2009403A1 (en) 1990-08-06
CA2009403C (en) 2000-10-31
ATE111529T1 (de) 1994-09-15
DE69012379T2 (de) 1995-03-09
EP0386882B1 (en) 1994-09-14
DK0386882T3 (da) 1994-12-12

Similar Documents

Publication Publication Date Title
DK0386882T3 (da) Pakningsdefekt HIV-provirus, cellelinier og anvendelse heraf
ES2056817T3 (es) Transformacion de trichoderma.
ES2091777T3 (es) Procedimiento para preparar un ensayo inmunologico de transferencia western.
ES2030057T3 (es) Una silice amorfa precipitada y su metodo de preparacion.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
ES2032194T3 (es) Solubilizacion de agregados proteicos.
SE8802818D0 (sv) Anordning for stapling av satsvis anordnade foremal
IT8022740A0 (it) Procedimento per la produzione di etanolo in forte concentrazione impiegando microorganismi immobilizzati.
EA200100943A1 (ru) Вич-пептиды, антигены, вакцинные композиции, набор для иммуноанализа и способ определения вич-индуцированных антител
DE3779905D1 (de) Zellkulturtraeger.
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
ATE54757T1 (de) Verfahren zum nachweis von htlv-iii neutralisierenden antikoerpern in sera.
DK280190D0 (da) Amfifile peptider og praeparater indeholdende saadanne
GB765552A (en) Improvements in or relating to apparatus for facilitating the handling of drums and like containers
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
SU940700A1 (ru) Удмуртский способ осветлени в смешанных молодн ках естественного происхождени
JPS5249544A (en) Vehicle lifting device
FI905055A0 (fi) Ett p1-bakteriofagkloningssystem foer sao stora dna-fragment som 95 kb.
ES2056858T3 (es) Esplenopentinas aciladas modificadas, procedimiento para su fabricacion y su uso.
BE838053A (fr) Recipient parallelepipedique transportable, du type container
DK467488D0 (da) Benzo(b)phenanthridinderivater samt deres fremstilling og anvendelse
JPS5377956A (en) Connecting mathod for two material

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 386882

Country of ref document: ES